Annexon, Inc. (ANNX)
3.92
-0.05
(-1.26%)
USD |
NASDAQ |
Nov 13, 16:00
3.93
+0.01
(+0.26%)
After-Hours: 19:59
Annexon Debt to Equity Ratio : 0.5126 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.5126 |
| June 30, 2026 | 0.1325 |
| March 31, 2026 | 0.1244 |
| December 31, 2025 | 0.1238 |
| September 30, 2025 | 0.1669 |
| June 30, 2025 | 0.1388 |
| March 31, 2025 | 0.1161 |
| December 31, 2024 | 0.0988 |
| September 30, 2024 | 0.0893 |
| June 30, 2024 | 0.0836 |
| March 31, 2024 | 0.1173 |
| December 31, 2023 | 0.1251 |
| September 30, 2023 | 0.2009 |
| June 30, 2023 | 0.1733 |
| March 31, 2023 | 0.1513 |
| December 31, 2022 | 0.1421 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.1293 |
| June 30, 2022 | 0.2031 |
| March 31, 2022 | 0.1704 |
| December 31, 2021 | 0.1491 |
| September 30, 2021 | 0.1279 |
| June 30, 2021 | 0.0894 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | -1.566 |
| June 30, 2019 | -1.369 |
| March 31, 2019 | |
| December 31, 2018 | -1.670 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0518 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1901 |
| Savara, Inc. | 0.2815 |
| Arrowhead Pharmaceuticals, Inc. | 27.84 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 250.41M |
| Total Liabilities (Quarterly) | 107.61M |
| Shareholders Equity (Quarterly) | 142.80M |
| Current Ratio | 5.786 |
| Net Debt Paydown Yield | -1.13% |